Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

DAPA-HF Trial Comm Investigators, J. J. V. McMurray*, S. D. Solomon, S. E. Inzucchi, L. Kober, M. N. Kosiborod, F. A. Martinez, P. Ponikowski, M. S. Sabatine, I. S. Anand, J. Belohlavek, M. Bohm, C. -E. Chiang, V. K. Chopra, R. A. de Boer, A. S. Desai, M. Diez, J. Drozdz, A. Dukat, J. GeJ. G. Howlett, T. Katova, M. Kitakaze, C. E. A. Ljungman, B. Merkely, J. C. Nicolau, E. O'Meara, M. C. Petrie, P. N. Vinh, M. Schou, S. Tereshchenko, S. Verma, C. Held, D. L. DeMets, K. F. Docherty, P. S. Jhund, O. Bengtsson, M. Sjostrand, A. -M. Langkilde

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

942 Citations (Scopus)



In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the presence or absence of type 2 diabetes.


In this phase 3, placebo-controlled trial, we randomly assigned 4744 patients with New York Heart Association class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either dapagliflozin (at a dose of 10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of worsening heart failure (hospitalization or an urgent visit resulting in intravenous therapy for heart failure) or cardiovascular death.


Over a median of 18.2 months, the primary outcome occurred in 386 of 2373 patients (16.3%) in the dapagliflozin group and in 502 of 2371 patients (21.2%) in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.65 to 0.85; P


Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than among those who received placebo, regardless of the presence or absence of diabetes.

Original languageEnglish
Pages (from-to)1995-2008
Number of pages14
JournalNew England Journal of Medicine
Issue number21
Publication statusPublished - 21-Nov-2019



Cite this